Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of Kapruvia® ...

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Commission has granted marketing authorization to Kapruvia® ...

Treatment with difelikefalin (Korsuva) significantly reduced pruritus within 12 weeks, according to a post-hoc analysis of the KALM-1 & KALM-2 phase III trials. Pooling data on maintenance ...

- FDA approval based on MARCH Phase 3 study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum ...

STAMFORD, Conn., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to ...

- First and only medication approved in both the U.S. and Europe to treat cholestatic pruritus in patients with Alagille syndrome. - Approval supported by more than six years of LIVMARLI data ...

Preliminary trial findings suggest transdermal cannabis may help ease pruritus-related itching in patients undergoing hemodialysis. Cannabis cream relieved itching symptoms over the short-term in a ...

Pruritus, or itching, is the unpleasant sensation that causes a desire to scratch. Chronic pruritus can be a debilitating manifestation of varied pathologies such as cholestasis, renal failure, and ...

"Uremic Pruritus Pipeline Insight"DelveInsight's,“Uremic Pruritus - Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Uremic Pruritus pipeline ...